Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

Here's a roundup of top developments in the biotech space over the last 24 hours:

Morning Brief: Top Stories Dominating Financial Media on Tuesday, March 22

Morning Brief: Top Stories Dominating Financial Media on Tuesday, March 22

Novartis Suspends Some Investment, Business Activities In Russia

Novartis Suspends Some Investment, Business Activities In Russia

Novartis AG (NYSE:NVS) will suspend capital investments, media advertising, and other promotional activities in Russia but remain committed to providing access to its medicine there. "Novartis condemns the war in Ukraine," it said in a statement, adding that "while we remain committed to providing access to our medicine in Russia, we responsibly…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs

Novartis AG (NYSE: NVS) has

‘It’s a real-life Hunger Games’: a lifesaving drug costs $2m, but not every child can get it

Zolgensma is a revolutionary gene therapy that can stop a deadly childhood condition called SMA in its tracks. It’s also one of the most expensive drugs in the world

The Guardian - UK

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have

inkl

Read news from The Economist, FT, and more,
with one subscription

Novartis Skids After Scrapping An Eczema Drug As Quarterly Metrics Lag

Novartis Skids After Scrapping An Eczema Drug As Quarterly Metrics Lag

Novartis stock tumbled Wednesday as fourth-quarter earnings lagged and after the Swiss pharma behemoth scrapped a promising eczema drug.

Investors Business Daily

Recap: Novartis Q4 Earnings

Recap: Novartis Q4 Earnings

Novartis (NYSE:NVS) reported its Q4 earnings results on Wednesday, February 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,

Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report

Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report

Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit (NYSE: NVS) Sandoz,

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

261,478 stories

109,429 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play